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Uncontrolled blood pressure (BP) in patients with chronic kidney disease (CKD) 
can lead to serious adverse outcomes. To prevent the occurrence of cardiovascu-
lar events (CVEs), and end-stage kidney disease, achieving an optimal BP level 
is important. Recently, there has been a paradigm shift in the management of 
BP largely as a result of the Systolic Blood Pressure Intervention Trial (SPRINT), 
which showed a reduction in CVEs by lowering systolic BP to 120 mmHg. A lower 
systolic blood pressure (SBP) target has been accepted by the Kidney Disease: Im-
proving Global Outcomes (KDIGO) 2021 guidelines. However, whether intensive 
control of SBP targeting < 120 mmHg is also effective in patients with CKD is 
controversial. Notably, this lower target SBP is associated with a higher risk of ad-
verse kidney outcomes. Unfortunately, there have been no randomized controlled 
trials on this issue involving only patients with CKD, particularly those with ad-
vanced CKD. In this review, we discuss the optimal control of BP in patients with 
CKD in terms of reduction in death and CVEs as well as attenuation of CKD pro-
gression based on the evidence-based literature.
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INTRODUCTION
Chronic kidney disease (CKD) and hypertension are 
closely connected and affect each other. Hypertensive 
kidney disease is the second most common cause of kid-
ney failure with replacement therapy (KFRT), and dete-
rioration of kidney function is accelerated by excessive 
high blood pressure (BP) [1-4]. Uncontrolled hyperten-
sion can cause adverse cardiovascular and cerebrovascu-
lar outcomes such as acute coronary syndrome, hemor-
rhagic and ischemic stroke, heart failure, and even death 
[5-10]. Therefore, in clinical practice, physicians typically 
prioritize BP control to preserve kidney function and re-
duce the rate of cardiovascular events (CVEs) and mor-
tality in patients with CKD.
Therefore, the question for consideration is, “What is 
the optimal target BP that will achieve these goals in pa-
tients with CKD?” Unfortunately, this issue has not yet 
been resolved. In addition to reducing the rate of adverse 
CVEs and mortality in patients with and without CKD, 
other important goals of BP control are to prevent the 
development of CKD for non-CKD patients and to at-
tenuate the deterioration of kidney function in patients 
with CKD. Epidemiologic studies have shown that, in 
patients without CKD, even a pre-hypertension level of 
systolic blood pressure (SBP; 130 to 140 mmHg) is asso-
ciated with a higher risk of CKD development compared 
with an SBP of < 120 mmHg [11-14]. In addition, a me-
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ta-analysis of observational data showed a higher risk of 
CVEs in individuals with an SBP of 120 to 129 mmHg 
compared to those with an SBP of < 120 mmHg [15]. No-
tably, guidelines from various countries do not agree on 
BP control in patients with CKD [16-22]. Over the last two 
decades, < 140/90 mmHg has typically been the target BP 
in patients without albuminuria and < 130/80 mmHg in 
those with albuminuria [17,23]. This conventional con-
cept has been challenged by the results of the Systol-
ic Blood Pressure Intervention Trial (SPRINT) study, 
which demonstrated the benefit of intensive control of 
SBP < 120 mmHg compared with the conventional tar-
get of < 140 mmHg [24]. The SPRINT study results are 
included in the Kidney Disease: Improving Global Out-
comes (KDIGO) 2021 guidelines, which suggest a target 
SBP of < 120 mmHg in patients with CKD [25]. However, 
not all studies favor this lower target, given the nega-
tive results of intensive BP control [26-28]. In fact, some 
guidelines still recommend the conventional BP target 
for patients with CKD [29-31]. BP targets in patients with 
CKD are listed in Table 1 [18,19,22,25,32-35].
In this article, we discuss the following three goals of 
optimal BP control in patients with CKD: (1) to prevent 
CVEs and all-cause death, (2) to prevent the develop-
ment of incident CKD, and (3) to delay the progression 
of CKD. Finally, we briefly describe conventional and 
potential drug therapies for improving outcomes in pa-
tients with CKD.
BP MEASUREMENT
The KDIGO 2021 BP guidelines recommend use of stan-
dardized rather than routine office BP measurement [25], 
as suggested by the 2017 American College of Cardiolo-
gy/American Heart Association (ACC/AHA) guidelines 
[32]. Standardized office BP measurement refers to BP 
measurement following the recommended preparation 
procedure. A summary of standardized office BP mea-
surement is provided in Table 2 [32]. In contrast, routine 
office BP measurement is performed without consid-
ering the recommended BP measurement procedure. 
Notably, BP readings using office BP measurement are 
typically higher than those using standardized BP mea-
surement [36]. BP measurement procedures vary among 
clinical trials, a critical point that should be considered 
when interpreting study results. However, for the sake 
of convenience, routine office BP measurement is com-
monly used in the real world. Given the possible risk of 
overtreatment and hypotension events associated with 
office BP measurement, use of standardized BP mea-
surement should be encouraged in clinical practice.
Table 1. Guideline comparisons of goal BP and first-line treatment for CKD patients with hypertension
Guideline
BP target in CKD  
patients without 
proteinuria, mmHg
BP target in CKD 




ISHIB [35] < 130/< 80 < 130/< 80 Diuretic or CCB
NICE [19] < 140/< 90 < 130/< 80 ACEi or ARB
JNC8 [18] < 140/< 90 < 140/< 90 ACEi or ARB
ACC/AHA [32] < 130/< 80 < 130/< 80 ACEi
ESC/ESH [34] SBP 130–139 SBP 130–139 ACEi or ARB
ISH [33] < 130/< 80 < 130/< 80 ACEi or ARB
Hypertension Canada [22] SBP < 120 SBP < 120 ACEi or ARB
KDIGO [25] SBP < 120 SBP < 120 ACEi or ARB
BP, blood pressure; CKD, chronic kidney disease; ISHIB, International Society on Hypertension in Blacks; CCB, calcium 
channel blocker; NICE, National Institute for Health and Clinical Excellence; ACEi, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; JNC8, Eighth Joint National Committee; ACC/AHA, American College of Cardiology/
American Heart Association; ESC/ESH, European Society of Cardiology and the European Society of Hypertension; SBP, 
systolic blood pressure; ISH, International Society of Hypertension; KDIGO, Kidney Disease: Improving Global Outcomes.
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BP CONTROL FOR PREVENTION OF CARDIO-
VASCULAR DISEASE AND DEATH IN CKD
Given the lack of randomized controlled trials (RCTs) 
in patients with only CKD, this issue has been evaluated 
by analyses of secondary outcomes. As mentioned above, 
the SPRINT study demonstrated that intensive control 
of SBP to < 120 mmHg resulted in better cardiovascu-
lar outcomes compared to control to < 140 mmHg [24]. 
This finding has been adopted by the ACC/AHA 2017 
guidelines [16] and the KDIGO 2021 guidelines [25]. No-
tably, the SPRINT study excluded patients with diabetes 
and a history of stroke. Most participants with CKD had 
CKD G3a; their mean estimated glomerular filtration 
rate (eGFR) was 48 mL/min/1.73 m2. Therefore, it is un-
clear whether intensive control using a lower BP target 
is beneficial in other risk groups, such as patients with 
diabetes or CKD G3b, G4, or G5. In the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial involv-
ing patients with type 2 diabetes, intensive control of 
SBP < 120 mmHg did not reduce the rate of a compos-
ite outcome of fatal and nonfatal major CVEs or death 
as compared with a standard target (< 140 mmHg), al-
though intensive control decreased the rate of nonfatal 
stroke events [26]. Nevertheless, 2,646 participants with 
an eGFR of < 60 mL/min/1.73 m2 in the SPRINT study 
provided adequate statistical power to examine the ef-
fect of intensive BP control on cardiovascular outcomes 
in patients with early CKD. In this separate analysis of 
participants with CKD, the intensive SBP intervention 
group had a 19% lower risk of composite cardiovascular 
outcomes and a 28% lower risk of all-cause death com-
pared to the standard BP control group [37]. In addition, 
in a meta-analysis of 123 trials including 613,815 partic-
ipants with BP lowering intervention, each 10 mmHg 
reduction in SBP significantly decreased the risk of ma-
jor CVEs and all-cause mortality [38]. Notably, a greater 
reduction in SBP resulted in a larger decrease in the rel-
ative risk of CVEs. That study also showed a significant 
risk reduction with a decrease in SBP in patients with 
CKD. However, a pooled analysis of four multicenter 
RCTs including 4,983 CKD patients with control of SBP 
to < 130 mmHg did not improve all-cause mortality and 
cardiovascular outcomes compared to standard control 
of SBP to < 140 mmHg [39]. In that study, the average 
BP achieved was 125.0 mmHg in the intensive group 
and 136.9 mmHg in the standard group. After exclud-
ing patients with an eGFR of ≥ 60 mL/min/1.73 m2 and 
intensive glucose control, the all-cause mortality rate 
was reduced in the intensive BP control group. Finally, 
in another meta-analysis of patients with CKD G3–G5, 
more intensive control (SBP 132 mmHg) resulted in a 
14.0% lower risk of all-cause mortality compared with 
less intensive control (SBP 140 mmHg) [40]. Therefore, 
the evidence supports intensive BP control to reduce ad-
verse CVE and all-cause mortality rates, even in patients 
with CKD. A summary of these RCTs is presented in Ta-
ble 3 [24,26,27,37,41,42]. In contrast to RCTs, analyses of 
Table 2. Summary of standardized office BP measurement 
Preparing the patient Caffeine, exercise, and smoking should be avoided for at least 30 minutes prior to measuring 
BP. Make sure the patient emptied their bladder before BP measurement. The patient 
should be seated in a chair with back support and feet placed on the floor, then relax for 
more than 5 minutes. The patient or the observer should not talk during the resting and 
measurement period. All clothing covering the cuff placing location should be removed.
Choosing the BP measurement 
for diagnosis and treatment of 
elevated BP
Measure BP from both arms on the first visit, and choose the arm with the higher BP for the 
following measurements. 
BP measuring technique Use validated BP measuring device, which should be regularly calibrated. Patient should 
have arm-support, with the cuff positioned on upper arm of patient. Use proper sized cuff, 
with the bladder 80% of the arm circumference.
Documentation of BP 
measurement
≥ 2 BP measurements with 1–2 minutes interval should be taken, and document the 
average of these BP measurements. Record both SBP, DBP, and the time of most recent BP 
medication intake prior to BP measurement.
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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observational cohort studies have shown a U-shaped as-
sociation between SBP and the risk of death in patients 
with CKD, suggesting a potential hazard for excessively 
low BP [43-46]. A low BP itself may reflect an unhealthy 
condition and underlying disease burden. 
BP CONTROL FOR THE PREVENTION OF CKD
No RCT has examined the effect of intensive BP control 
on the development of incident CKD. Studies on this 
issue are mostly post hoc analyses of RCTs comparing 
the effect of intensive versus standard BP control in pa-
tients with high cardiovascular risk. Among these, the 
ACCORD trial showed that intensive control of SBP 
< 120 mmHg increased the risk of incident CKD [26]. 
In line with this study, a similar SBP intervention in 
the SPRINT study resulted in a higher frequency of ad-
verse kidney outcomes among patients without diabe-
tes [24]. Therefore, intensive BP control is not beneficial 
for preserving kidney function. However, intensive BP 
control is effective in reducing albuminuria. Despite the 
increased risk of CKD, the ACCORD trial showed a sig-
nificant reduction in macroalbuminuria by intensive BP 
control. In a similarly designed RCT involving patients 
with type 2 diabetes, active BP control significantly re-
duced the risk of microalbuminuria and macroalbu-
minuria [47,48]. A reduction in albuminuria by intensive 
BP control was also found in a meta-analysis of 19 RCTs 
including both diabetic and non-diabetic patients [49]. 
For the prevention of CKD, these studies indicate that 
intensive BP control carries both a risk and a benefit: 
a decline in eGFR and reduction in albuminuria. To 
mitigate concerns on the increase in the risk of adverse 
kidney outcomes by intensive BP control, the SPRINT 
and ACCORD investigators showed that various kid-
ney injury markers were not elevated in the intensive 
BP control group, suggesting that the increased serum 
creatinine level was associated with hemodynamic alter-
ations [50,51]. Despite the debate on its validity as a sur-
rogate marker of renal function, albuminuria is widely 
accepted as an appropriate target or surrogate marker 
for kidney disease progression [52]. The United States 
Food and Drug Administration recently agreed to use 
early change in albuminuria as a surrogate marker for 
kidney disease progression in phase 3 trials dealing with 
diseases involving moderate to severe albuminuria, and 
intervention trials in which decreasing albuminuria is 
presumed to be the primary mechanism of action [53]. 
The key findings of major RCTs are shown in Table 4.
In contrast to previous RCTs involving patients 
with an increased risk of CVD and a baseline SBP of 
≥ 130 mmHg, observational studies provide compre-
hensive information on individuals at low risk of CKD 
and few comorbidities, even those without pre-existing 
hypertension. Interestingly, there was a graded relation 
ship between SBP and the risk of incident CKD, and the 
risk was lower for an SBP of < 120 mmHg [11-13,54,55]. 
We observed similar findings in two large representa-
tive Korean adult cohorts using meticulous analytical 
approaches [56,57]. These findings raised the question of 
whether reducing SBP to < 120 mmHg in individuals 
with hypertension and at high risk of CVD is equiva-
lent to an intrinsically normal BP in healthy adults. In 
summary, intensive BP control for the prevention of in-
cident CKD has not yet been justified. If kidney injury 
associated with intensive BP control is minimal and re-
versible, a lower BP target can be implemented in clini-
cal practice with a permissive decline in eGFR given the 
proven benefit on prevention of adverse CVEs.
BP CONTROL FOR DELAYING THE PROGRES-
SION OF CKD
CKD progression is generally faster in patients with 
than in those without diabetes. In non-diabetic patients 
with CKD, three clinical trials have evaluated the effect 
of intensive BP control on CKD progression: the Mod-
ification of Diet in Renal Disease (MDRD) study; the 
AASK trial; and the Blood Pressure Control for Reno-
protection in Patients with Non-diabetic Chronic Renal 
Disease (REIN-2) trial [28,58,59]. The African-American 
Study of Kidney Disease and Hypertension (AASK) and 
REIN-2 trials excluded patients with diabetes. Only 
5% of participants in the MDRD study were patients 
with diabetes. The target BPs in the intensive con-
trol arm were < 125/75 mmHg (mean arterial pressure 
< 92 mmHg) for the MDRD study and < 130/80 mmHg 
for the AASK and the REIN-2 trials. The MDRD study, 
published in 1994, showed that the beneficial effect of a 
lower BP target was particularly evident in patients with 
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daily urinary protein excretion > 1.0 g [59]. Long-term 
follow-up of the MDRD study with observation extend-
ed to 10 years also showed that CKD outcomes and the 
all-cause mortality rate were decreased by intensive BP 
control [60]. However, the AASK and REIN-2 trials failed 
to delay the progression of CKD or the development of 
KFRT in patients with intensive BP control. Notably, in 
the AASK trial, a subgroup of patients with CKD and a 
protein-to-creatinine ratio of ≥ 0.22 g/g in the intensive 
BP control group had a significant reduction in the risk 
of KFRT or death. These findings suggest that intensive 
BP control is more effective in non-diabetic patients 
with CKD and significant proteinuria. A systemic review 
and meta-analysis supports the ability of intensive con-
trol of BP < 130/80 mmHg to attenuate CKD progression 
in non-diabetic patients with CKD and significant pro-
teinuria [61,62].
The clinical benefits of intensive BP control are unclear 
in patients with type 2 diabetes. The BP goals in most 
early studies were > 140 mmHg, which was considered 
suboptimal [41,42,63,64]. The Appropriate Blood Control 
in Diabetes (ABCD) study evaluated the effect of a lower 
BP target of < 130/80 mmHg on the preservation of kid-
ney function in patients with type 2 diabetes compared 
with a standard control of < 140/90 mmHg but failed to 
demonstrate a benefit of intensive BP control [65]. How-
ever, two post hoc analyses of the Reduction of Endpoints 
in Non-Insulin-Dependent Diabetes Mellitus with the 
Angiotensin II Antagonist Losartan (RENAAL) and the 
Irbesartan Diabetic Nephropathy Trial (IDNT) showed 
that a lower BP level was associated with improved kid-
ney outcomes [66,67]. In contrast to the less-intensive 
BP targets in the studies above, the intervention in the 
ACCORD trial lowered SBP to < 120 mmHg [26]. How-
ever, as discussed above, a lower target BP increased the 
frequency of adverse kidney events such as an elevated 
serum creatinine level or a decline in eGFR of < 30 mL/
min/1.73 m2. It should be noted that the ACCORD study 
excluded patients with a serum creatinine level of > 1.5 
mg/dL; therefore, the participants were unlikely to be 
representative of patients with CKD and diabetes. We 
have summarized the results of major RCTs on this top-
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DRUG TREATMENT
Besides achieving the optimal BP, choosing medica-
tions with renoprotective effects is important. A detailed 
description of this issue is beyond the scope of this re-
view. Here, we briefly describe conventional drugs and 
introduce several with potential for prevention of CKD 
progression.
Renin-angiotensin system blockers (RASBs), such as 
angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin receptor blockers (ARB), are a cornerstone 
therapy in patients with CKD. In a groundbreaking 
study by Lewis et al. [68], captopril was first used to pro-
tect against a decline in kidney function in patients with 
insulin-dependent type 1 diabetes and CKD studies with 
RASBs have consistently demonstrated the renoprotec-
tive effects of these drugs, including a reduction in pro-
teinuria and attenuation of eGFR decline. These bene-
ficial effects were evident in patients with and without 
diabetes. In the AASK trial, patients randomly assigned 
to ramipril showed a slower decline in eGFR compared 
to those on other treatments [69]. In patients with type 2 
diabetes and CKD, the RENAAL and IDNT studies con-
firmed the superior protective effects of ARBs against 
the progression of CKD [70,71]. RASBs have been tested 
in patients with early CKD, even those without microal-
buminuria. In the Bergamo Nephrologic Diabetes Com-
plications Trial (BENEDICT), ACEi prevented the onset 
of microalbuminuria in patients with type 2 diabetes 
and normal urinary albumin excretion [72]. All guide-
lines recommend the use of RASBs as first-line therapy 
based on high-quality evidence [18,19,22,25,32-34].
RASBs cannot stop the progression of CKD and no 
other drugs are used widely in clinical practice. Recent-
ly, many studies with new anti-diabetic drugs, such as 
sodium-glucose co-transporter 2 inhibitors (SGLT2i) 
and glucagon-like peptide-1 receptor agonists (GLP1RA), 
have consecutively demonstrated outstanding renopro-
tective effects [73,74]. The American Diabetes Association 
(ADA), the European Association for the Study of Diabe-
tes (EASD), and the KDIGO accepted the results of these 
studies and recommend SGLT2i and GLP1RA as first-
line therapies for patients with diabetic kidney disease 
[75,76]. Interestingly, these drugs have also been reported 
to reduce adverse CVEs and death [77-79]. Moreover, in 
the Dapagliflozin and Prevention of Adverse Outcomes 
in Chronic Kidney Disease (DAPA-CKD) trial, dapagli-
flozin reduced the risk of the composite outcome of kid-
ney failure or death from renal or cardiovascular causes 
even in non-diabetic patients with CKD [80]. In addi-
tion, these drugs can reduce BP by 5 mmHg [79,81,82].
Atrasentan is a highly selective endothelin receptor A 
receptor (ETAR) antagonist, the short-term use of which 
reportedly reduces albuminuria in patients with diabet-
ic nephropathy [83]. The Study of Diabetic Nephropathy 
with Atrasentan (SONAR) tested the long-term effect 
of atrasentan in 2,648 patients with type 2 diabetes and 
overt albuminuria [84]. Atrasentan resulted in a signif-
icant reduction in the composite adverse kidney out-
come of doubling serum creatinine or KFRT. A recent 
phase 2 study of sparsentan, a dual ETAR antagonist 
and ARB, also showed a significant reduction in pro-
teinuria in patients with primary focal segmental glo-
merulosclerosis [85]. ETAR antagonists are reported to 
decrease BP [85,86]. The effects of ETAR antagonists are 
under investigation in other primary glomerular diseas-
es (NCT03762850, NCT03493685, NCT04573478).
Finally, mineralocorticoid receptor antagonists (MRAs) 
have renoprotective and cardioprotective effects [87-89]. 
It also reduces BP in individuals with resistant hyperten-
sion [90,91]. Spironolactone, a first-generation nonselec-
tive MRA, was initially reported to provide renoprotec-
tive effects by reducing proteinuria and preserving eGFR 
in non-diabetic patients with CKD [87]. Recently, finere-
none, a new-generation selective MRA, has emerged as a 
potential therapy. In the Finerenone in Reducing Kidney 
Failure and Disease Progression in Diabetic Kidney Dis-
ease (FIDELIO-DKD) study, finerenone reduced the risk 
of CKD progression and the development of CVEs in pa-
tients with CKD and type 2 diabetes [92]. These drugs are 
promising and expected to improve kidney survival and 
major clinical outcomes in combination with RASBs. 
Table 5 lists clinical trials of drug treatments [68,70-
72,74,77,78,80,84,85,87,92,93].
CONCLUSIONS
In patients with CKD, the scope of ‘optimal BP control’ 
should encompass improved cardiovascular outcomes, 
reduced mortality, and delayed CKD progression. How-
ever, despite much research, the optimal BP reduction 
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to achieve these goals has not been determined. Table 
6 presents a summary of BP control based on the KDI-
GO 2021 guidelines. These recommendations and sug-
gestions are helpful in clinical practice, and the guide-
lines support intensive BP control targeting an SBP of 
< 120 mmHg because the cardiovascular benefits of SBP 
intervention outweigh the risk of kidney injury associat-
ed with the lower BP target. However, many uncertain-
ties remain to be resolved in future trials. We anticipate 
that a greater number of well-designed RCTs will assess 
the effects of intensive BP control by various interven-
tions in diverse groups of patients with CKD with and 
without diabetes, a high cardiovascular risk, or protein-
uria, and with early versus late CKD.
Conflict of interest
No potential conflict of interest relevant to this article 
was reported.
REFERENCES
1. Oh KH, Kang M, Kang E, et al. The KNOW-CKD Study: 
what we have learned about chronic kidney diseases. Kid-
ney Res Clin Pract 2020;39:121-135. 
2. Son HE, Ryu JY, Go S, et al. Association of ambulatory 
blood pressure monitoring with renal outcome in pa-
tients with chronic kidney disease. Kidney Res Clin Pract 
2020;39:70-80. 
3. Ezzatzadegan Jahromi S, Haghighi G, Roozbeh J, Ebra-
himi V. Comparisons between different blood pressure 
measurement techniques in patients with chronic kidney 
disease. Kidney Res Clin Pract 2019;38:212-219. 
4. Kim K, Lee SH, Lee SW, Lee JP, Chin HJ; Korean Glomer-
uloNEphritis sTudy (KoGNET) Group. Current findings 
of kidney biopsy including nephropathy associated with 
hypertension and diabetes mellitus in Korea. Korean J 
Intern Med 2020;35:1173-1187. 
5. Kim H, Yoo TH, Choi KH, et al. Baseline cardiovascular 
characteristics of adult patients with chronic kidney 
disease from the KoreaN Cohort Study for Outcomes in 
Patients With Chronic Kidney Disease (KNOW-CKD). J 
Korean Med Sci 2017;32:231-239. 
6. Jha V, Modi GK. Getting to know the enemy better-the 
global burden of chronic kidney disease. Kidney Int 
2018;94:462-464. 
7. Kim KM, Oh HJ, Choi HY, Lee H, Ryu DR. Impact of 
chronic kidney disease on mortality: a nationwide cohort 
study. Kidney Res Clin Pract 2019;38:382-390. 
8. Baek SH, Cha RH, Kang SW, et al. Circulating renalase 
predicts all-cause mortality and renal outcomes in pa-
tients with advanced chronic kidney disease. Korean J 
Intern Med 2019;34:858-866. 
9. Lee C, Yun HR, Joo YS, et al. Framingham risk score and 
risk of incident chronic kidney disease: a communi-
ty-based prospective cohort study. Kidney Res Clin Pract 
Table 6. Key BP control recommendations and suggestions by the KDIGO 2021 guideline 
BP management in patients with non-dialysis CKD, with, or without diabetes.
Recommendation 1 We recommend adults with high BP and CKD be treated with a target SBP < 120 mmHg, when 
tolerated, using standardized office BP measurement (2B).
Recommendation 2 We recommend starting RASi (ACEi or ARB) for people with high BP, CKD, and severely 
increased albuminuria (G1–G4, A3) without diabetes (1B).
Recommendation 3 We recommend starting RASi (ACEi or ARB) for people with high BP, CKD, and moderately 
increased albuminuria (G1–G4, A2) without diabetes (2C).
Recommendation 4 We recommend starting RASi (ACEi or ARB) for people with high BP, CKD, and moderately-to-
severely increased albuminuria (G1–G4, A2, and A3) with diabetes (1B).
Recommendation 5 We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) 
therapy in patients with CKD, with or without diabetes (1B).
1B, strong recommendation based on moderate quality evidence; 2C, weak recommendation based on low quality evidence; A1, 
ACR < 30 mg/g (< 3 mg/mmol); A2, ACR 30–300 mg/g (3–30 mg/mmol); A3, ACR > 300 mg/g (> 30 mg/mmol).
BP, blood pressure; KDIGO, Kidney Disease: Improving Global Outcomes; CKD, chronic kidney disease; SBP, systolic blood 




Lee JY and Han SH. BP control in CKD
www.kjim.orghttps://doi.org/10.3904/kjim.2021.181 
2019;38:49-59. 
10. Park S. Management plans for populations with nor-
mal-to-hypertensive blood pressures: risks and benefits 
of antihypertensive drug treatment in populations pre-
viously defined as having high-normal blood pressure. 
Korean J Intern Med 2019;34:44-49. 
11. Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predic-
tors of new-onset decline in kidney function in a general 
middle-european population. Nephrol Dial Transplant 
2008;23:1265-1273.
12. Reynolds K, Gu D, Muntner P, et al. A population-based, 
prospective study of blood pressure and risk for 
end-stage renal disease in China. J Am Soc Nephrol 
2007;18:1928-1935. 
13. Xue H, Wang J, Hou J, et al. Prehypertension and chronic 
kidney disease in chinese population: four-year follow-up 
study. PLoS One 2015;10:e0144438. 
14. Garofalo C, Borrelli S, Pacilio M, et al. Hypertension and 
prehypertension and prediction of development of de-
creased estimated GFR in the general population: a me-
ta-analysis of cohort studies. Am J Kidney Dis 2016;67:89-
97. 
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; 
Prospective Studies Collaboration. Age-specific relevance 
of usual blood pressure to vascular mortality: a me-
ta-analysis of individual data for one million adults in 61 
prospective studies. Lancet 2002;360:1903-1913. 
16. Colantonio LD, Booth JN 3rd, Bress AP, et al. 2017 ACC/
AHA blood pressure treatment guideline recommen-
dations and cardiovascular risk. J Am Coll Cardiol 
2018;72:1187-1197. 
17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC 
guidelines for the management of arterial hypertension: 
the task force for the management of arterial hyperten-
sion of the European Society of Hypertension (ESH) and 
of the European Society of Cardiology (ESC). Eur Heart J 
2013;34:2159-2219. 
18. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based 
guideline for the management of high blood pressure 
in adults: report from the panel members appointed 
to the Eighth Joint National Committee (JNC 8). JAMA 
2014;311:507-520. 
19. Jaques H; National Institute for Health and Clinical Ex-
cellence (NICE). NICE guideline on hypertension. Eur 
Heart J 2013;34:406-408. 
20. Weber MA, Schiffrin EL, White WB, et al. Clinical prac-
tice guidelines for the management of hypertension in 
the community a statement by the American Society of 
Hypertension and the International Society of Hyperten-
sion. J Hypertens 2014;32:3-15. 
21. Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 
clinical practice guideline for the evaluation and man-
agement of chronic kidney disease: summary of recom-
mendation statements. Kidney Int Suppl 2013;3:5-14.
22. Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hyper-
tension Canada’s 2020 comprehensive guidelines for the 
prevention, diagnosis, risk assessment, and treatment 
of hypertension in adults and children. Can J Cardiol 
2020;36:596-624. 
23. Becker GJ, Wheeler DC, De Zeeuw D, et al. KDIGO clin-
ical practice guideline for the management of blood 
pressure in chronic kidney disease. Kidney Int Suppl 
2012;2:337-414.
24. SPRINT Research Group, Wright JT Jr, Williamson JD, 
et al. A randomized trial of intensive versus standard 
blood-pressure control. N Engl J Med 2015;373:2103-2116. 
25. Kidney Disease: Improving Global Outcomes (KDIGO) 
Blood Pressure Work Group. KDIGO 2021 clinical prac-
tice guideline for the management of blood pressure in 
chronic kidney disease. Kidney Int 2021;99:S1-S87. 
26. ACCORD Study Group, Cushman WC, Evans GW, et al. 
Effects of intensive blood-pressure control in type 2 dia-
betes mellitus. N Engl J Med 2010;362:1575-1585. 
27. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pres-
sure lowering in intermediate-risk persons without car-
diovascular disease. N Engl J Med 2016;374:2009-2020. 
28. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure 
control for renoprotection in patients with non-diabetic 
chronic renal disease (REIN-2): multicentre, randomised 
controlled trial. Lancet 2005;365:939-946. 
29. Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hy-
pertension: the ESH/ESC guidelines recommendations. 
Pharmacol Res 2018;128:315-321. 
30. Pilmore H, Dogra G, Roberts M, et al. Cardiovascular dis-
ease in patients with chronic kidney disease. Nephrology 
(Carlton) 2014;19:3-10. 
31. Prichard S. Clinical practice guidelines of the Canadian 
Society of Nephrology for the treatment of patients with 
chronic renal failure: a re-examination. Contrib Nephrol 
2003;140:163-169. 
32. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/
AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA 
       
792 www.kjim.org https://doi.org/10.3904/kjim.2021.181 
The Korean Journal of Internal Medicine Vol. 36, No. 4, July 2021
guideline for the prevention, detection, evaluation, and 
management of high blood pressure in adults: a report 
of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines. 
Hypertension 2018;71:e13-e115. 
33. Unger T, Borghi C, Charchar F, et al. 2020 International 
Society of Hypertension global hypertension practice 
guidelines. J Hypertens 2020;38:982-1004. 
34. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH 
guidelines for the management of arterial hypertension: 
the task force for the management of arterial hyperten-
sion of the European Society of Cardiology and the Euro-
pean Society of Hypertension: the task force for the man-
agement of arterial hypertension of the European Society 
of Cardiology and the European Society of Hypertension. 
J Hypertens 2018;36:1953-2041. 
35. Flack JM, Sica DA, Bakris G, et al. Management of high 
blood pressure in Blacks: an update of the International 
Society on Hypertension in Blacks consensus statement. 
Hypertension 2010;56:780-800. 
36. Ahmad FS, Chan C, Rosenman MB, et al. Validity of car-
diovascular data from electronic sources: the multi-eth-
nic study of atherosclerosis and HealthLNK. Circulation 
2017;136:1207-1216. 
37. Cheung AK, Rahman M, Reboussin DM, et al. Effects 
of intensive BP control in CKD. J Am Soc Nephrol 
2017;28:2812-2823. 
38. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure 
lowering for prevention of cardiovascular disease and 
death: a systematic review and meta-analysis. Lancet 
2016;387:957-967. 
39. Aggarwal R, Petrie B, Bala W, Chiu N. Mortality outcomes 
with intensive blood pressure targets in chronic kidney 
disease patients. Hypertension 2019;73:1275-1282. 
40. Malhotra R, Nguyen HA, Benavente O, et al. Association 
between more intensive vs less intensive blood pressure 
lowering and risk of mortality in chronic kidney disease 
stages 3 to 5: a systematic review and meta-analysis. JAMA 
Intern Med 2017;177:1498-1505. 
41. UK Prospective Diabetes Study Group. Tight blood pres-
sure control and risk of macrovascular and microvas-
cular complications in type 2 diabetes: UKPDS 38. BMJ 
1998;317:703-713. 
42. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of 
intensive blood-pressure lowering and low-dose aspirin 
in patients with hypertension: principal results of the 
Hypertension Optimal Treatment (HOT) randomised tri-
al. HOT Study Group. Lancet 1998;351:1755-1762. 
43. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved 
blood pressure on cardiovascular outcomes in the Irbe-
sartan Diabetic Nephropathy Trial. J Am Soc Nephrol 
2005;16:2170-2179. 
44. Kovesdy CP, Lu JL, Molnar MZ, et al. Observational mod-
eling of strict vs conventional blood pressure control in 
patients with chronic kidney disease. JAMA Intern Med 
2014;174:1442-1449. 
45. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. 
Impact of achieved blood pressures on mortality risk and 
end-stage renal disease among a large, diverse hyperten-
sion population. J Am Coll Cardiol 2014;64:588-597.
46. Navaneethan SD, Schold JD, Jolly SE, et al. Blood pressure 
parameters are associated with all-cause and cause-spe-
cific mortality in chronic kidney disease. Kidney Int 
2017;92:1272-1281. 
47. Patel A; ADVANCE Collaborative Group, MacMahon S, et 
al. Effects of a fixed combination of perindopril and in-
dapamide on macrovascular and microvascular outcomes 
in patients with type 2 diabetes mellitus (the ADVANCE 
trial): a randomised controlled trial. Lancet 2007;370:829-
840. 
48. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering 
blood pressure reduces renal events in type 2 diabetes. J 
Am Soc Nephrol 2009;20:883-892. 
49. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pres-
sure lowering on cardiovascular and renal outcomes: 
updated systematic review and meta-analysis. Lancet 
2016;387:435-443. 
50. Nadkarni GN, Chauhan K, Rao V, et al. Effect of intensive 
blood pressure lowering on kidney tubule injury: find-
ings from the ACCORD Trial Study participants. Am J 
Kidney Dis 2019;73:31-38. 
51. Rocco MV, Sink KM, Lovato LC, et al. Effects of inten-
sive blood pressure treatment on acute kidney injury 
events in the Systolic Blood Pressure Intervention Trial 
(SPRINT). Am J Kidney Dis 2018;71:352-361. 
52. Heerspink HJL, Greene T, Tighiouart H, et al. Change 
in albuminuria as a surrogate endpoint for progression 
of kidney disease: a meta-analysis of treatment effects in 
randomised clinical trials. Lancet Diabetes Endocrinol 
2019;7:128-139. 
53. Levey AS, Gansevoort RT, Coresh J, et al. Change in albu-
minuria and GFR as end points for clinical trials in early 
793
 
Lee JY and Han SH. BP control in CKD
www.kjim.orghttps://doi.org/10.3904/kjim.2021.181 
stages of CKD: a scientific workshop sponsored by the 
National Kidney Foundation in collaboration with the US 
Food and Drug Administration and European Medicines 
Agency. Am J Kidney Dis 2020;75:84-104. 
54. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren 
C. Elevated blood pressure and risk of end-stage renal 
disease in subjects without baseline kidney disease. Arch 
Intern Med 2005;165:923-928. 
55. Schaeffner ES, Kurth T, Bowman TS, Gelber RP, Gaziano 
JM. Blood pressure measures and risk of chronic kidney 
disease in men. Nephrol Dial Transplant 2008;23:1246-
1251. 
56. Chang TI, Lim H, Park CH, et al. Associations of systolic 
blood pressure with incident CKD G3-G5: a cohort study 
of South Korean adults. Am J Kidney Dis 2020;76:224-232.
57. Joo YS, Lee C, Kim HW, et al. Association of longitudinal 
trajectories of systolic BP with risk of incident CKD: re-
sults from the Korean Genome and Epidemiology Study. 
J Am Soc Nephrol 2020;31:2133-2144. 
58. Appel LJ, Wright JT Jr, Greene T, et al. Intensive 
blood-pressure control in hypertensive chronic kidney 
disease. N Engl J Med 2010;363:918-929. 
59. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary 
protein restriction and blood-pressure control on the 
progression of chronic renal disease. Modification of Diet 
in Renal Disease Study Group. N Engl J Med 1994;330:877-
884. 
60. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower 
target blood pressure on the progression of kidney dis-
ease: long-term follow-up of the modification of diet in 
renal disease study. Ann Intern Med 2005;142:342-351. 
61. Tsai WC, Wu HY, Peng YS, et al. Association of intensive 
blood pressure control and kidney disease progression 
in nondiabetic patients with chronic kidney disease: a 
systematic review and meta-analysis. JAMA Intern Med 
2017;177:792-799. 
62. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive 
blood pressure lowering on the progression of chronic 
kidney disease: a systematic review and meta-analysis. 
CMAJ 2013;185:949-957. 
63. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuret-
ic-based antihypertensive treatment on cardiovascular 
disease risk in older diabetic patients with isolated systolic 
hypertension. Systolic Hypertension in the Elderly Pro-
gram Cooperative Research Group. JAMA 1996;276:1886-
1892. 
64. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects 
of calcium-channel blockade in older patients with di-
abetes and systolic hypertension. Systolic Hypertension 
in Europe Trial Investigators. N Engl J Med 1999;340:677-
684. 
65. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of ag-
gressive blood pressure control in normotensive type 
2 diabetic patients on albuminuria, retinopathy and 
strokes. Kidney Int 2002;61:1086-1097. 
66. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood 
pressure level on progression of diabetic nephropa-
thy: results from the RENAAL study. Arch Intern Med 
2003;163:1555-1565.
67. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Indepen-
dent and additive impact of blood pressure control and 
angiotensin II receptor blockade on renal outcomes in 
the irbesartan diabetic nephropathy trial: clinical impli-
cations and limitations. J Am Soc Nephrol 2005;16:3027-
3037. 
68. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect 
of angiotensin-converting-enzyme inhibition on diabetic 
nephropathy. The Collaborative Study Group. N Engl J 
Med 1993;329:1456-1462. 
69. Agodoa LY, Appel L, Bakris GL, et al. Effect of rami-
pril vs amlodipine on renal outcomes in hypertensive 
nephrosclerosis: a randomized controlled trial. JAMA 
2001;285:2719-2728. 
70. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan 
in patients with nephropathy due to type 2 diabetes. N 
Engl J Med 2001;345:851-860. 
71. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of lo-
sartan on renal and cardiovascular outcomes in patients 
with type 2 diabetes and nephropathy. N Engl J Med 
2001;345:861-869. 
72. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microal-
buminuria in type 2 diabetes. N Engl J Med 2004;351:1941-
1951. 
73. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglu-
tide and renal outcomes in type 2 diabetes: an exploratory 
analysis of the REWIND randomised, placebo-controlled 
trial. Lancet 2019;394:131-138.
74. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and re-
nal outcomes in type 2 diabetes and nephropathy. N Engl 
J Med 2019;380:2295-2306. 
75. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of 
       
794 www.kjim.org https://doi.org/10.3904/kjim.2021.181 
The Korean Journal of Internal Medicine Vol. 36, No. 4, July 2021
hyperglycemia in type 2 diabetes, 2018. A consensus re-
port by the American Diabetes Association (ADA) and the 
European Association for the Study of Diabetes (EASD). 
Diabetes Care 2018;41:2669-2701. 
76. Kidney Disease: Improving Global Outcomes (KDIGO) 
Diabetes Work Group. KDIGO 2020 clinical practice 
guideline for diabetes management in chronic kidney 
disease. Kidney Int 2020;98:S1-S115. 
77. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and 
cardiovascular and renal events in type 2 diabetes. N Engl 
J Med 2017;377:644-657. 
78. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin 
and progression of kidney disease in type 2 diabetes. N 
Engl J Med 2016;375:323-334. 
79. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 
2019;380:347-357. 
80. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. 
Dapagliflozin in patients with chronic kidney disease. N 
Engl J Med 2020;383:1436-1446. 
81. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering 
effects of GLP-1 receptor agonists exenatide and liraglu-
tide: a meta-analysis of clinical trials. Diabetes Obes Me-
tab 2013;15:737-749.
82. Majewski C, Bakris GL. Blood pressure reduction: an 
added benefit of sodium-glucose cotransporter 2 in-
hibitors in patients with type 2 diabetes. Diabetes Care 
2015;38:429-430. 
83. Kohan DE, Pritchett Y, Molitch M, et al. Addition of at-
rasentan to renin-angiotensin system blockade reduces 
albuminuria in diabetic nephropathy. J Am Soc Nephrol 
2011;22:763-772. 
84. Heerspink HJL, Parving HH, Andress DL, et al. Atrasen-
tan and renal events in patients with type 2 diabetes and 
chronic kidney disease (SONAR): a double-blind, ran-
domised, placebo-controlled trial. Lancet 2019;393:1937-
1947.
85. Trachtman H, Nelson P, Adler S, et al. DUET: a phase 2 
study evaluating the efficacy and safety of sparsentan in 
patients with FSGS. J Am Soc Nephrol 2018;29:2745-2754. 
86. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety 
of atrasentan in patients with cardiovascular risk and ear-
ly atherosclerosis. Hypertension 2008;52:522-528. 
87. Bianchi S, Bigazzi R, Campese VM. Long-term effects 
of spironolactone on proteinuria and kidney function 
in patients with chronic kidney disease. Kidney Int 
2006;70:2116-2123. 
88. Pitt B, Zannad F, Remme WJ, et al. The effect of spirono-
lactone on morbidity and mortality in patients with 
severe heart failure. Randomized Aldactone Evaluation 
Study Investigators. N Engl J Med 1999;341:709-717.
89. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selec-
tive aldosterone blocker, in patients with left ventricular 
dysfunction after myocardial infarction. N Engl J Med 
2003;348:1309-1321. 
90. Williams B, MacDonald TM, Morant S, et al. Spirono-
lactone versus placebo, bisoprolol, and doxazosin to 
determine the optimal treatment for drug-resistant hy-
pertension (PATHWAY-2): a randomised, double-blind, 
crossover trial. Lancet 2015;386:2059-2068. 
91. Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone 
versus clonidine as a fourth-drug therapy for resistant 
hypertension: the ReHOT Randomized Study (Resis-
tant Hypertension Optimal Treatment). Hypertension 
2018;71:681-690. 
92. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone 
on chronic kidney disease outcomes in type 2 diabetes. N 
Engl J Med 2020;383:2219-2229. 
93. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of da-
pagliflozin on development and progression of kidney 
disease in patients with type 2 diabetes: an analysis from 
the DECLARE-TIMI 58 randomised trial. Lancet Diabetes 
Endocrinol 2019;7:606-617. 
